Norwegian Finans Holding ASA
The Board of Directors in Norwegian Finans Holding ASA ("the Company") refers to the announcement at 08.00 CET at 4 March, where Nordax Bank AB announces its intention to launch a voluntary offer for the shares in the company. The Board of Directors will consider any offer launched. Shareholders are advised to refrain from taking any action in respect of their shares in the Company, before the Board of Directors has given their recommendation, and to exercise caution when dealing in the shares of the Company. Such actions may be prejudicial to shareholders interests. There can be no certainty that any offer will be made or completed. Further announcements will be made as required.
For any questions please call:
Klaus-Anders Nysteen, Chairman of the Board of Directors, phone: +47 99 26 56 91 / + 46 72-566 54 15
Tine Wollebekk, CEO, phone: +47 40 80 55 57
Klara-Lise Aasen, CFO, phone: +47 47 63 55 83
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Robex Resources Inc.21.12.2025 23:28:03 CET | Press release
Robex Pours First Gold at Kiniéro on Schedule and Budget
ALK Abello19.12.2025 22:46:46 CET | Press release
Major shareholder announcement
ALK Abello19.12.2025 22:46:46 CET | Pressemeddelelse
Storaktionærmeddelelse
Zealand Pharma19.12.2025 22:00:00 CET | Press release
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Boehringer Ingelheim Limited19.12.2025 21:10:00 CET | Press release
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
